We have to look at patients holistically, who have kidney disease and diabetes, to address the totality of risks, certainly progression to kidney failure, but also prevention of cardiovascular events and deaths. Ozempic and other GLP-1s will be compared to another diabetes drug class, SGLT-2 inhibitors Given Ozempics reduction of kidney disease events in the FLOW study, it seems likely that the GLP-1s will be used together with and compared against SGLT-2 inhibitor drugs
Serious side effects from Ozempic are rare
DOI: 10.1056/NEJMoa2307563 Masharani U, Kroon L (2024): Pancreatic Hormones & Antidiabetic Drugs (Chapter 41)
Patients who had a patient-reported change in body weight of more than 5kg within 90 days before screening and a history of diabetes were excluded from the study
The side effect profiles for semaglutide and tirzepatide are better characterized because both medications have been on the market longer
We also evaluated the impact of semaglutide on the measured proteome in a single model for men versus women, including an interaction term between treatment and sex
